SSE News / China Securities Online (Reporter: Li Yanzheng) — Sunshine Novo announced on January 21, 2026, that its investigational small nucleic acid drug, ABA001, has formally received Clinical Trial Application (IND) acceptance from the National Medical Products Administration (NMPA). The drug is targeting hypertension, marking a pivotal step forward for the company’s nucleic acid drug platform.
ABA001 utilizes GalNAc covalent conjugation technology to precisely deliver siRNA into hepatocytes, specifically degrading AGT mRNA to effectively “shut off” the pressor switch of the Renin-Angiotensin-Aldosterone System (RAAS). Non-clinical data demonstrate that a single subcutaneous injection can produce rapid and sustained blood-pressure-lowering effects in animal models, accompanied by a favorable safety profile.
Classified as a Category 1 innovative chemical drug, ABA001 is intended for the treatment of primary hypertension. It offers the potential for quarterly or even semi-annual dosing, a significant improvement over existing daily medications. According to the regulatory review process, if no objections are raised within 60 days, the project will immediately commence Phase I clinical trials. The company revealed that it has synchronized its subsequent clinical and industrialization plans, striving for an early New Drug Application (NDA) to provide a "long-acting, precise, and affordable" nucleic acid drug solution for hypertension control in China.
Sunshine Novo’s transition toward innovation has yielded fruitful results. Its established platforms—the "AI Peptide Innovative Drug R&D Platform," "Small Nucleic Acid AOC R&D Platform," and "Novel CAR-T Drug Development Platform"—are progressing smoothly. Several drugs are currently in the clinical development stage. Among them, STC007, a non-addictive postoperative analgesic, is progressing well in Phase III clinical trials and is expected to submit its NDA in 2026, potentially becoming the company’s first approved innovative drug.
In addition to the hypertension pipeline, the company is rapidly advancing small nucleic acid and AOC (Antibody-Oligonucleotide Conjugates) pipelines for indications such as fat loss/muscle gain, hyperglycemia, Alzheimer’s disease, and COPD. Sunshine Novo believes that the inherent advantages of small nucleic acid drugs—long-acting, stable, and precise—will reshape the therapeutic landscape for these conditions.

https://finance.eastmoney.com/a/202601213626191568.html